2023 World Conference on Lung Cancer (Posters)-EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2) - PDF(Slides)

Back to course

Pdf Summary

A study conducted by Wily Pandu Ariawan at Dharmais National Cancer Center Hospital in Indonesia aimed to investigate the expression of a specific microRNA, miR-320b, in non-small cell lung cancer (NSCLC) and its potential as a prognostic factor. The study involved 16 NSCLC patients who received either chemotherapy or tyrosine kinase inhibitor (TKI) therapy. Blood samples were taken before and after therapy, and the expression of miR-320b in extracellular vesicles (EVs) was analyzed.<br /><br />The results showed that after therapy, the expression of miR-320b increased, although not significantly. The study also evaluated the response to therapy in different patient groups, including partial response, stable disease, and progressive disease. The levels of miR-320b varied in these groups, with the partial response group experiencing a decrease in miR-320b levels, the stable disease group showing a slight decrease, and the progressive disease group showing an increase. However, there was no significant relationship between miR-320b levels and treatment response.<br /><br />The study also analyzed the clinical characteristics of the study subjects, including age, gender, weight, and treatment history. It was found that the median level of miR-320b in the partial response and stable disease groups decreased, while it increased in the progressive disease group. Interestingly, there was no significant difference in miR-320b levels between patients receiving chemotherapy and TKI therapy.<br /><br />The findings suggest that miR-320b may play a role in the growth and development of NSCLC. The decrease in miR-320b expression in some patient groups and the increase in others may be a response to therapy and an effort to inhibit the progression of cancer cells. However, further research is needed to validate these findings and explore the potential of miR-320b as a prognostic factor and therapeutic target for NSCLC.<br /><br />It is important to note that these findings are based on a specific study and further research is needed to better understand the role of miR-320b in NSCLC and its potential clinical implications.

Asset Subtitle

Wily Ariawan

Meta Tag

Speaker Wily Ariawan

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

microRNA

miR-320b

non-small cell lung cancer

NSCLC

prognostic factor

chemotherapy

tyrosine kinase inhibitor

extracellular vesicles

treatment response

therapeutic target